Overt and Masked Polycythemia Vera Within the Scope of Ph-Negative Myeloproliferative Diseases

ZhV Tratsevskaya, AM Kovrigina, DI Chebotarev, AL Melikyan, AO Abdullaev, AB Sudarikov

National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167

For correspondence: Prof. Alla Mikhailovna Kovrigina, PhD in Biology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167; Tel.: +7(495)612-61-12; e-mail: kovrigina.alla@gmail.com

For citation: Tratsevskaya ZhV, Kovrigina AM, Chebotarev DI, et al. Overt and Masked Polycythemia Vera Within the Scope of Ph-negative Myeloproliferative Diseases. Clinical oncohematology. 2020;13(1):58–66 (In Russ).

DOI: 10.21320/2500-2139-2020-13-1-58-66


Aim. To study the structure of Ph-negative myeloproliferative diseases (Ph– MPD) and to identify morphological markers for diagnosing masked polycythemia vera (PV).

Materials & Methods. Bone marrow core biopsy samples from the database of pathology department of National Research Center for Hematology within the period from January 2014 to June 2017 provided the basis for analyzing the diagnosed Ph– MPD cases. The trial included the bone marrow core biopsy samples of the patients treated and followed-up not only at the National Research Center for Hematology but also at other medical centers in the Russian Federation in the context of clinical, laboratory and molecular data.

Results. In 1611 Ph– MPD patients PV prevailed corresponding to 40.6 % of all cases. In the PV group the masked form was diagnosed in 29 % of patients. Primary myelofibrosis (PMF) was diagnosed in 26.6 % of all patients including 10 % of cases with pre-fibrosis/early stage. The 3d most frequent disorder was essential thrombocythemia (ET) which corresponded to 16 %. JAK2 driver mutation was identified in all 654 PV patients. In 4 cases out of them exon 12 mutation was detected. A similar mutation was found out in PMF (53 %) and ET (60 %). In 36 % of PMF patients and 27 % of ET patients CALR mutation was detected. MPL mutation was identified in 4 % of PMF cases and was not discovered in ET. Triple negative patients were identified in 7 % of PMF and 13 % of ET cases. The designation of “myeloproliferative disease unclassifiable” can be applied to 16.8 % of cases. The trial deals with morphological criteria for diagnosing masked PV during examination of bone marrow core biopsy samples. In 30 % of patients with masked PV (according to the 2017 WHO classification) and splenomegaly (> 14 cm) portal vein thrombosis was identified.

Conclusion. In the Ph– MPD group PV diagnosis prevailed (40.6 %). The histological analysis of bone marrow core biopsy samples of the patients with the masked PV accounting for 29 % of all PV cases, revealed morphological features typical of overt PV. Histological analysis of bone marrow is a reliable method for diagnosing overt and masked PV. Among morphological characteristics of the bone marrow of patients with masked PV and portal vein thrombosis special attention should be paid to the MF-1 grade of reticulin fibrosis (29 % of cases) and loose clusters of megakaryocytes (71.4 %).

Keywords: Ph-negative myeloproliferative disease/neoplasms, masked polycythemia vera, pathomorphology, bone marrow core biopsy.

Received: September 14, 2019

Accepted: December 12, 2019

Read in PDF


  1. Swerdlow SH, Campo E, Harris NL, et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition). Lyon: IARC Press; 2017. 585 p.

  2. Gianelli U, Bossi A, Cortinovis I, et al. Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms. Mod Pathol. 2014;27(6):814–22. doi: 10.1038/modpathol.2013.196.

  3. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379–90. doi: 10.1056/NEJMoa1311347.

  4. Pietra D, Rumi E, Ferretti VV, et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia. 2016;30(2):431–8. doi: 10.1038/leu.2015.277.

  5. Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014;28(7):1472–7. doi: 10.1038/leu.2014.3.

  6. Zamora L, Xicoy B, Cabezon M, et al. Co-existence of JAK2 V617F and CALR mutations in primary myelofibrosis. Leuk Lymphoma. 2015;56(10):2973–4. doi: 10.3109/10428194.2015.1015124.

  7. Lin Y, Liu E, Sun Q, et al. The prevalence of JAK2, MPL, and CALR mutations in Chinese patients with BCR-ABL1-negative myeloproliferative neoplasms. Am J Clin Path. 2015;144(1):165–71. doi: 10.1309/AJCPALP51XDIXDDV.

  8. Ahmed RZ, Rashid M, Ahmed N, et al. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms – Do They Designate a New Subtype? Asian Pacif J Cancer Prevent. 2016;17(3):923–6. doi: 10.7314/apjcp.2016.17.3.923.

  9. Bowman RL, Busque L, Levine RL. Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies. Cell Stem Cell. 2018;22(2):157–70. doi: 10.1016/j.stem.2018.01.011.

  10. Shlush LI. Age-related clonal hematopoiesis. Blood. 2018;131(5):496–504. doi: 10.1182/blood-2017-07-746453.

  11. Steensma DP, Bejar R. Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126(1):9–16. doi: 10.1182/blood-2015-03-631747.

  12. Gianelli U, Iurlo A, Vener C, et al. The Significance of Bone Marrow Biopsy and JAK2V617F Mutation in the Differential Diagnosis Between the “Early” Prepolycythemic Phase of Polycythemia Vera and Essential Thrombocythemia. Am J Clin Pathol. 2008;130(3):336–42. doi: 10.1309/6BQ5K8LHVYAKUAF4.

  13. Thiele J, Kvasnicka HM, Zankovich R, Diehl V. The value of bone marrow histology in differentiating between early stage polycythemia vera and secondary (reactive) polycythemias. Haematologica. 2001;86(4):368–74.

  14. Barbui T, Thiele J, Vannucchi AM, et al. Rethinking the diagnostic criteria of polycythemia vera. Leukemia. 2013;28(6):1191–5. doi: 10.1038/leu.2013.380.

  15. Thiele J, Kvasnicka HM, Diehl V. Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia. Acta Haematol. 2005;113(4):213–9. doi: 10.1159/000084673.

  16. Barbui T, Thiele J, Carobbio A, et al. Masked polycythemia vera diagnosed according to WHO and BCSH classification. Am J Hematol. 2014;89(2):199–202. doi: 10.1002/ajh.23617.

  17. Kvasnicka HM, Orazi A, Thiele J, et al. European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia. Am J Hematol. 2017;92(10):1062–7. doi 10.1002/ajh.24837.

  18. Ковригина А.М., Байков В.В. Истинная полицитемия: новая концепция диагностики и клинические формы. Клиническая онкогематология. 2016;9(2):115–22. doi: 10.21320/2500-2139-2016-9-2-115-122.

    [Kovrigina AM, Baikov VV. Polycythemia Vera: New Diagnostic Concept and Its Types. Clinical oncohematology. 2016;9(2):115–22. doi: 10.21320/2500-2139-2016-9-2-115-122. (In Russ)]

  19. Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: An alternative proposal. Blood. 2008;112(2):231–9. doi: 10.1182/blood-2007-12-128454.

  20. Silver RT, Chow W, Orazi A, et al. Evaluation of WHO criteria for diagnosis of polycythemia vera: A prospective analysis. Blood. 2013;122(11):1881–6. doi: 10.1182/blood-2013-06-508416.

  21. McMullin MF, Reilly JT, Campbell P, et al. Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. Br J Haematol. 2007;138(6):821–2. doi: 10.1111/j.1365-2141.2007.06741.x.

  22. Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol. 1999;36(1 Suppl 2):9–13.

  23. Lussana F, Carobbio A, Randi ML, et al. A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia Vera. Br J Haematol. 2014;167(4):541–6. doi: 10.1111/bjh.13080.

  24. Меликян А.Л., Туркина А.Г., Ковригина А.М. и др. Клинические рекомендации по диагностике и терапии Ph-негативных миелопролиферативных заболеваний (истинная полицитемия, эссенциальная тромбоцитемия, первичный миелофиброз) (редакция 2016 г.). Гематология и трансфузиология. 2017;62(1, прил. 1):25–60. doi: 10.18821/0234-5730-2017-62-1-S1-1-60.

    [Melikyan AL, Turkina AG, Kovrigina AM, et al. Clinical recommendations for diagnosis and therapy of Ph-negative myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, primary myelofibrosis) (edition 2016). Gematologiya i transfuziologiya. 2017;62(1 Suppl 1):25–60. doi: 10.18821/0234-5730-2017-62-1-S1-1-60. (In Russ)]

  25. Суборцева И.Н., Колошейнова Т.И., Пустовая Е.И. и др. Истинная полицитемия: обзор литературы и собственные данные. Клиническая онкогематология. 2015;8(4):397–412. doi: 10.21320/2500-2139-2015-8-4-397-412.

    [Subortseva IN, Kolosheinova TI, Pustovaya EI, et al. Polycythemia Vera: Literature Review and Own Data. Clinical oncohematology. 2015;8(4):397–412. doi: 10.21320/2500-2139-2015-8-4-397-412. (In Russ)]

  26. Barbui T, Thiele J, Vannucchi AM, Tefferi A. Myeloproliferative neoplasms: Morphology and clinical practice. Am J Hematol. 2016;91(4):430–3. doi: 10.1002/ajh.24288.

  27. Wong WJ, Hasserjian RP, Pinkus GS, et al. JAK2, CALR, MPL and ASXL1 mutational status correlates with distinct histological features in Philadelphia chromosome-negative myeloproliferative neoplasms. Haematologica. 2018;103(2):e63–e68. doi: 10.3324/haematol.2017.178988.

  28. Alvarez-Larran A, Ancochea A, Gracia M, et al. WHO-histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes. Br J Haematol. 2014;166(6):911–9. doi: 10.1111/bjh.12990.